» Articles » PMID: 3855684

Differing Determinants of Prognosis Following Resection of Pulmonary Metastases from Osteogenic and Soft Tissue Sarcoma Patients

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1985 Mar 15
PMID 3855684
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A study was performed to determine if prognostic factors could be used preoperatively to predict outcome following resection of metastases. Sixty-seven soft tissue sarcoma (STS) patients (median follow-up, 36 months) and 39 osteogenic sarcoma patients (OGS) (median follow-up, 29 months) underwent thoracic exploration at the first indication of pulmonary metastases, and the results for each group were reviewed. The number of metastatic nodules, disease-free interval (DFI), and tumor doubling time (TDT) significantly correlated with postoperative survival for STS patients. Patients with four or fewer nodules on preoperative linear tomograms survived longer (median, 23 months) than patients with more than four nodules (median, 6 months; P less than 0.005). Patients with a DFI greater than 12 months had a longer survival (median, 30 months) than patients with a DFI less than or equal to 12 months (median, 10 months; P less than 0.005). Patients with a TDT greater than or equal to 20 days had a longer survival (median, 22 months) than patients with a TDT less than 20 days (median, 6 months; P less than 0.005). The only significant predictor of survival for OGS patients was the number of nodules on preoperative linear tomograms (less than or equal to 4, 37 months median survival; greater than 4, 10 months median survival; P less than 0.05). This was due to significant differences noted for the DFI and TDT distributions between OGS and STS patients, with most OGS patients having a short DFI (less than or equal to 12 months) and a rapid TDT (less than or equal to 20 days) whereas STS patients had a more heterogeneous distribution (P less than 0.01). Thus, the number of metastases visible on the preoperative tomogram was the best predictor of survival for both OGS and STS patients. However, the applicability of other prognostic factors could not be generalized for these two closely related groups of patients.

Citing Articles

The Critical Role of Stereotactic Body Radiation Therapy in Multimodal Treatment of Lung Metastasis from Bone and Soft Tissue Sarcomas.

Longhi A, Marrari A, Tetta C, Parmeggiani A, Parise O, Ferrari C Cancers (Basel). 2024; 16(21).

PMID: 39518034 PMC: 11544818. DOI: 10.3390/cancers16213593.


Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?.

Gamboa A, Ethun C, Switchenko J, Lipscomb J, Poultsides G, Grignol V J Am Coll Surg. 2019; 229(5):449-457.

PMID: 31377411 PMC: 6815708. DOI: 10.1016/j.jamcollsurg.2019.07.010.


Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Ann Oncol. 2018; 29(4):857-871.

PMID: 29432564 PMC: 6354678. DOI: 10.1093/annonc/mdy052.


Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.

ONeill A, Towbin A, Krailo M, Xia C, Gao Y, McCarville M J Clin Oncol. 2017; 35(30):3465-3473.

PMID: 28892430 PMC: 5648177. DOI: 10.1200/JCO.2017.73.5654.


Impact of tumor volume doubling time on post-metastatic survival in bone or soft-tissue sarcoma patients treated with metastasectomy and/or radiofrequency ablation of the lung.

Nakamura T, Matsumine A, Takao M, Nakatsuka A, Matsubara T, Asanuma K Onco Targets Ther. 2017; 10:559-564.

PMID: 28203089 PMC: 5293497. DOI: 10.2147/OTT.S121562.